215 related articles for article (PubMed ID: 19295477)
1. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents.
Li Y; Liu B; Zhao H; Sailhamer EA; Fukudome EY; Zhang X; Kheirbek T; Finkelstein RA; Velmahos GC; deMoya M; Hales CA; Alam HB
Shock; 2009 Nov; 32(5):517-23. PubMed ID: 19295477
[TBL] [Abstract][Full Text] [Related]
2. Surviving lethal septic shock without fluid resuscitation in a rodent model.
Li Y; Liu B; Fukudome EY; Kochanek AR; Finkelstein RA; Chong W; Jin G; Lu J; deMoya MA; Velmahos GC; Alam HB
Surgery; 2010 Aug; 148(2):246-54. PubMed ID: 20561658
[TBL] [Abstract][Full Text] [Related]
3. Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock.
Li Y; Liu B; Fukudome EY; Lu J; Chong W; Jin G; Liu Z; Velmahos GC; Demoya M; King DR; Alam HB
Surgery; 2011 Sep; 150(3):442-51. PubMed ID: 21878229
[TBL] [Abstract][Full Text] [Related]
4. Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock.
Finkelstein RA; Li Y; Liu B; Shuja F; Fukudome E; Velmahos GC; deMoya M; Alam HB
J Surg Res; 2010 Sep; 163(1):146-54. PubMed ID: 20599223
[TBL] [Abstract][Full Text] [Related]
5. Creating a "pro-survival" phenotype through epigenetic modulation.
Li Y; Liu B; Gu X; Kochanek AR; Fukudome EY; Liu Z; Zhao T; Chong W; Zhao Y; Zhang D; Libermann TA; Alam HB
Surgery; 2012 Sep; 152(3):455-64. PubMed ID: 22938904
[TBL] [Abstract][Full Text] [Related]
6. Citrullinated histone H3: a novel target for the treatment of sepsis.
Li Y; Liu Z; Liu B; Zhao T; Chong W; Wang Y; Alam HB
Surgery; 2014 Aug; 156(2):229-34. PubMed ID: 24957671
[TBL] [Abstract][Full Text] [Related]
7. Novel pharmacologic treatment attenuates septic shock and improves long-term survival.
Zhao T; Li Y; Liu B; Liu Z; Chong W; Duan X; Deperalta DK; Velmahos GC; Alam HB
Surgery; 2013 Aug; 154(2):206-13. PubMed ID: 23889949
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents.
Zhao Y; Zhou P; Liu B; Bambakidis T; Mazitschek R; Alam HB; Li Y
J Surg Res; 2015 Apr; 194(2):544-550. PubMed ID: 25479907
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages.
Chong W; Li Y; Liu B; Zhao T; Fukudome EY; Liu Z; Smith WM; Velmahos GC; deMoya MA; Alam HB
J Surg Res; 2012 Dec; 178(2):851-9. PubMed ID: 22868051
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.
Chong W; Li Y; Liu B; Liu Z; Zhao T; Wonsey DR; Chen C; Velmahos GC; deMoya MA; King DR; Kung AL; Alam HB
J Trauma Acute Care Surg; 2012 Feb; 72(2):347-53; discussion 353-4. PubMed ID: 22327976
[TBL] [Abstract][Full Text] [Related]
11. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
[TBL] [Abstract][Full Text] [Related]
12. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans.
Sailhamer EA; Li Y; Smith EJ; Shuja F; Shults C; Liu B; Soupir C; deMoya M; Velmahos G; Alam HB
Surgery; 2008 Aug; 144(2):204-16. PubMed ID: 18656627
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors trichostatin A and suberoylanilide hydroxamic acid attenuate ventilator-induced lung injury.
Chen HY; Li L; Fu ZJ
Pharmazie; 2014 Jan; 69(1):55-9. PubMed ID: 24601225
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice.
Li X; Yuan M; Yin R; Liu X; Zhang Y; Sun S; Han L; He S
Sci Rep; 2019 Jul; 9(1):9859. PubMed ID: 31285488
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
Li Y; Zhao T; Liu B; Halaweish I; Mazitschek R; Duan X; Alam HB
J Trauma Acute Care Surg; 2015 Feb; 78(2):378-85. PubMed ID: 25757125
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
18. Selective histone deacetylase 6 inhibition prolongs survival in a lethal two-hit model.
Cheng X; Liu Z; Liu B; Zhao T; Li Y; Alam HB
J Surg Res; 2015 Jul; 197(1):39-44. PubMed ID: 25837686
[TBL] [Abstract][Full Text] [Related]
19. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Reilly CM; Mishra N; Miller JM; Joshi D; Ruiz P; Richon VM; Marks PA; Gilkeson GS
J Immunol; 2004 Sep; 173(6):4171-8. PubMed ID: 15356168
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses.
Bodas M; Mazur S; Min T; Vij N
Respir Res; 2018 Jan; 19(1):2. PubMed ID: 29301535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
